GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Highnoon Laboratories Ltd (KAR:HINOON) » Definitions » 5-Year EBITDA Growth Rate

Highnoon Laboratories (KAR:HINOON) 5-Year EBITDA Growth Rate : 27.50% (As of Mar. 2025)


View and export this data going back to 1998. Start your Free Trial

What is Highnoon Laboratories 5-Year EBITDA Growth Rate?

Highnoon Laboratories's EBITDA per Share for the three months ended in Mar. 2025 was ₨28.65.

During the past 12 months, Highnoon Laboratories's average EBITDA Per Share Growth Rate was 46.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 25.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 27.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Highnoon Laboratories was 34.20% per year. The lowest was 16.40% per year. And the median was 25.50% per year.


Competitive Comparison of Highnoon Laboratories's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Highnoon Laboratories's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Highnoon Laboratories's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Highnoon Laboratories's 5-Year EBITDA Growth Rate falls into.


;
;

Highnoon Laboratories 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Highnoon Laboratories  (KAR:HINOON) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Highnoon Laboratories 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Highnoon Laboratories's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Highnoon Laboratories Business Description

Traded in Other Exchanges
N/A
Address
Jail Road, 901-9th floor, Tricon Corporate Center 73-E, Lahore, PAK
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.

Highnoon Laboratories Headlines

No Headlines